Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Activated Brown Fat Controls Obesity and Metabolic Disorders

By BiotechDaily International staff writers
Posted on 08 May 2013
Image: First author Dr. Aaron Cypess is an assistant professor of medicine at Harvard Medical School (Photo courtesy of Joslin Diabetes Center, Beth Deaconess Medical Center, Harvard University Medical School).
Image: First author Dr. Aaron Cypess is an assistant professor of medicine at Harvard Medical School (Photo courtesy of Joslin Diabetes Center, Beth Deaconess Medical Center, Harvard University Medical School).
Researchers speculate that the development of new drugs to activate human brown adipose tissue (BAT) could lead to safe treatments for obesity and metabolic disorders.

White adipose tissue (WAT) stores excess calories, while BAT consumes molecular fuel for thermogenesis (heat generation) using the tissue-specific enzyme UCP1(uncoupling protein 1).

Investigators at Harvard Medical School (Boston, MA, USA) delved into the genetic expression and protein activities found in BAT to determine its possible future role in the treatment of obesity. To this end, they isolated neck fat from adult human volunteers and compared its gene expression, differentiation capacity, basal oxygen consumption, and oxygen consumption rate (OCR), to different mouse adipose depots.

Among findings reported in the April 21, 2013, online edition of the journal Nature Medicine was that the OCR of the human BAT cells from the deep location in the neck next to the longus colli was nearly 50% of the rate found for mouse BAT cells. In contrast, the OCR of human WAT was only one-hundredth of the OCR found in the most active human BAT from the longus colli depot.

The investigators established a protocol for growth in culture of new functional BAT cells (adipocytes) by differentiating precursor cells (preadipocytes) derived from both superficial and deep human neck fat tissue. When stimulated, these cells expressed the same genes as naturally occurring brown fat cells. The use of brown fat cells produced in vitro will encourage development of drugs and other treatments that increase BAT activity for the correction of obesity and other metabolic disorders.

“BAT is most abundant in the deep locations of the neck, close to the sympathetic chain and the carotid arteries, where it likely helps to warm blood and raise body temperature,” said first author Dr. Aaron M. Cypess, assistant professor of medicine at Harvard Medical School. “Now that we know where brown fat is, we can easily collect more cells for further study.”

“Our research has significant practical applications. If we stimulate the growth of brown fat in people, it may burn their white fat and help them lose weight, which lessens insulin resistance and improves diabetes,” said Dr. Cypess.

Related Links:

Harvard Medical School


Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.